CA3096591C - Dosing regimens for treatment of proliferative disorders - Google Patents

Dosing regimens for treatment of proliferative disorders Download PDF

Info

Publication number
CA3096591C
CA3096591C CA3096591A CA3096591A CA3096591C CA 3096591 C CA3096591 C CA 3096591C CA 3096591 A CA3096591 A CA 3096591A CA 3096591 A CA3096591 A CA 3096591A CA 3096591 C CA3096591 C CA 3096591C
Authority
CA
Canada
Prior art keywords
curcumin
curcuminoids
dmpc
dmpg
lysophosphatidylcholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3096591A
Other languages
English (en)
French (fr)
Other versions
CA3096591A1 (en
Inventor
Peter Sordillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of CA3096591A1 publication Critical patent/CA3096591A1/en
Application granted granted Critical
Publication of CA3096591C publication Critical patent/CA3096591C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3096591A 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders Active CA3096591C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655095P 2018-04-09 2018-04-09
US62/655,095 2018-04-09
PCT/US2019/024495 WO2019199469A1 (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
CA3096591A1 CA3096591A1 (en) 2019-10-17
CA3096591C true CA3096591C (en) 2023-06-27

Family

ID=68164516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096591A Active CA3096591C (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Country Status (11)

Country Link
US (2) US11813356B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773529B1 (cg-RX-API-DMAC7.html)
JP (2) JP7241426B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240027843A (cg-RX-API-DMAC7.html)
CN (1) CN112272555A (cg-RX-API-DMAC7.html)
AU (1) AU2019250832B2 (cg-RX-API-DMAC7.html)
CA (1) CA3096591C (cg-RX-API-DMAC7.html)
ES (1) ES3061642T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020010651A (cg-RX-API-DMAC7.html)
TW (1) TWI737974B (cg-RX-API-DMAC7.html)
WO (1) WO2019199469A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
EP4675742A4 (en) 2023-02-28 2026-06-17 Panasonic Ip Man Co Ltd SECONDARY BATTERY WITH NON-AQUEAL ELECTROLYTE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1299085B1 (en) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
US8563525B2 (en) * 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
UA99914C2 (ru) 2007-05-15 2012-10-25 Оцука Фармас'Ютікел Ко., Лтд. Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
CN101766619B (zh) * 2008-12-30 2011-08-24 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
EP2501372A4 (en) 2009-11-19 2013-04-10 Signpath Pharma Inc INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER
HK1208907A1 (en) 2012-06-14 2016-03-18 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
WO2014036534A1 (en) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
WO2015077640A1 (en) 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
JP6895252B2 (ja) * 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ikrチャネルの薬剤誘発性阻害のリポソームによる軽減
KR101755245B1 (ko) 2015-08-12 2017-07-07 연세대학교 원주산학협력단 단량체 염을 이용한 폴리이미드 복합체 제조방법
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Also Published As

Publication number Publication date
EP3773529C0 (en) 2025-12-24
KR102637598B1 (ko) 2024-02-16
KR20200141062A (ko) 2020-12-17
EP3773529A1 (en) 2021-02-17
AU2019250832B2 (en) 2022-10-27
CA3096591A1 (en) 2019-10-17
ES3061642T3 (en) 2026-04-06
US20210161815A1 (en) 2021-06-03
US11813356B2 (en) 2023-11-14
EP3773529A4 (en) 2021-12-22
TW201946613A (zh) 2019-12-16
JP2023030106A (ja) 2023-03-07
US20240050372A1 (en) 2024-02-15
AU2019250832A1 (en) 2020-10-29
MX2020010651A (es) 2021-01-15
EP3773529B1 (en) 2025-12-24
US12551436B2 (en) 2026-02-17
KR20240027843A (ko) 2024-03-04
CN112272555A (zh) 2021-01-26
WO2019199469A1 (en) 2019-10-17
JP7241426B2 (ja) 2023-03-17
JP2021521130A (ja) 2021-08-26
TWI737974B (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
Greil et al. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
JP6861682B2 (ja) コエンザイムQ10(CoQ10)の静脈内投与用製剤およびその使用方法
US7968115B2 (en) Liposomal curcumin for treatment of cancer
JP5645954B2 (ja) イリノテカン又はその塩酸塩のリポソーム及びその製造方法
US12551436B2 (en) Dosing regimens for treatment of proliferative disorders
US20080103213A1 (en) Liposomal curcumin for treatment of neurofibromatosis
Yu et al. Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells
HK1221638A1 (zh) 使用辅酶q10联合疗法治疗癌症
Abeesh et al. Preparation and characterization of withaferin A loaded pegylated nanoliposomal formulation with high loading efficacy: In vitro and in vivo anti-tumour study
Liu et al. Coloaded nanoparticles of paclitaxel and piperlongumine for enhancing synergistic antitumor activities and reducing toxicity
CN114652683B (zh) 一种Mdivi-1纳米长循环脂质体及其制备方法和应用
CN115364218A (zh) 一种特定药脂比的药物组合物在抗肿瘤中的应用
US20150147385A1 (en) Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
HK40044373A (en) Dosing regimens for treatment of proliferative disorders
US20210338583A1 (en) Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
Yu et al. Nanomedicine strategies for acute respiratory distress syndrome management
KR101735284B1 (ko) 젬시타빈이 포집된 면역 리포좀 및 베바시주맙을 유효성분으로 포함하는 교모세포종 예방 및 치료용 약학적 조성물
HK40078790A (en) Pharmaceutical composition containing elemene, preparation method therefor, and use thereof
EP3071190A1 (en) Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
BR102013005601B1 (pt) Composição farmaceutica contendo lipossomas convencionais e lipossomas de circulaqao prolongada para o tratamento da leishmaniose visceral

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201008

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250407

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260220

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260506